Literature DB >> 23218471

Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?

Marta Bonotto1, Claudia Bozza, Carla Di Loreto, Etin-Osa O Osa, Elena Poletto, Fabio Puglisi.   

Abstract

Thymidine phosphorylase (TP) expression has been found to be elevated in various solid tumors where it is likely involved in mechanisms that regulate cell proliferation, apoptosis, and angiogenesis. Based on these properties, it is tempting to hypothesize a potential prognostic role of TP, suggesting that a high TP expression could predict a poor outcome. On the other hand, TP expression has been studied for its role in predicting benefit from treatment with fluoropyrimidine-containing chemotherapy. Several studies have been conducted on breast cancer. The current evidence on the value of TP is not mature enough to allow its translation into clinical practice. However, several findings support the potentially predictive role of TP. In this light, TP appears to be a promising marker that can give helpful information to predict the benefit from capecitabine-based chemotherapy in patients with breast cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218471     DOI: 10.1016/j.clbc.2012.10.002

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  8 in total

Review 1.  Identifying therapeutic targets in gastric cancer: the current status and future direction.

Authors:  Beiqin Yu; Jingwu Xie
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-15       Impact factor: 3.848

2.  Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.

Authors:  Qiong Wei; Haijuan Liu; Honghao Zhou; Dejun Zhang; Zhiwei Zhang; Qibing Zhou
Journal:  BMC Cancer       Date:  2015-03-21       Impact factor: 4.430

3.  A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.

Authors:  Vincenzo De Falco; Maria Iole Natalicchio; Stefania Napolitano; Nicola Coppola; Giovanni Conzo; Erika Martinelli; Nicoletta Zanaletti; Pasquale Vitale; Emilio Francesco Giunta; Maria Teresa Vietri; Pietro Paolo Vitiello; Davide Ciardiello; Anna Marinaccio; Ferdinando De Vita; Fortunato Ciardiello; Teresa Troiani
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Thymidine Phosphorylase Expression and Microvascular Density Correlation Analysis in Canine Mammary Tumor: Possible Prognostic Factor in Breast Cancer.

Authors:  Nicola Zizzo; Giuseppe Passantino; Roberta Maria D'alessio; Antonella Tinelli; Giuseppe Lopresti; Rosa Patruno; Domenico Tricarico; Fatima Maqoud; Rosa Scala; Francesco Alfredo Zito; Girolamo Ranieri
Journal:  Front Vet Sci       Date:  2019-10-25

5.  FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients.

Authors:  Ning Xie; Can Tian; Hui Wu; Xiaohong Yang; Liping Liu; Jing Li; Huawu Xiao; Jianxiang Gao; Jun Lu; Xuming Hu; Min Cao; Zhengrong Shui; Yu Tang; Xiao Wang; Jianbo Yang; Zhe-Yu Hu; Quchang Ouyang
Journal:  Ther Adv Med Oncol       Date:  2020-05-11       Impact factor: 8.168

6.  Liver as a source for thymidine phosphorylase replacement in mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Elisa Boschetti; Roberto D'Alessandro; Francesca Bianco; Valerio Carelli; Giovanna Cenacchi; Antonio D Pinna; Massimo Del Gaudio; Rita Rinaldi; Vincenzo Stanghellini; Loris Pironi; Kerry Rhoden; Vitaliano Tugnoli; Carlo Casali; Roberto De Giorgio
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

7.  Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Authors:  Manuela Terranova-Barberio; Maria Serena Roca; Andrea Ilaria Zotti; Alessandra Leone; Francesca Bruzzese; Carlo Vitagliano; Giosuè Scogliamiglio; Domenico Russo; Giovanni D'Angelo; Renato Franco; Alfredo Budillon; Elena Di Gennaro
Journal:  Oncotarget       Date:  2016-02-16

8.  Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Authors:  Christoph Zielinski; Istvan Lang; Semir Beslija; Zsuzsanna Kahan; Moshe J Inbar; Salomon M Stemmer; Rodica Anghel; Damir Vrbanec; Diethelm Messinger; Thomas Brodowicz
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.